Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc.) on July 25, 2018. The filing addresses Item 5.02 regarding the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation grants and does not contain financial performance data for the period.
Material Changes
The material change reported is the approval of new equity-based compensation awards by the Board of Directors on July 25, 2018:
- Standard Grants: Restricted Stock Units (RSUs) and stock options were granted to key executives. RSUs vest on the third anniversary; options vest monthly over 36 months.
- Long-Term Incentive Plan (LTIP): A plan for fiscal year 2021 was approved, tying RSU awards to the company's Earnings Per Share (EPS) performance. Awards range from 50% to 150% of the target amount based on EPS achievement.
Guidance, Outlook, and Risks
The filing does not provide general business guidance, outlook, or risk factors. However, it notes a specific contingency for the LTIP: eligibility for the performance-based RSUs is subject to the participating employees continuing as employees of the Company through the last day of fiscal year 2021.
Important Facts for Investors to Verify
- Company Identity: Verify that the filing pertains to Landec Corporation, as the metadata request mentioned Lifecore Biomedical, Inc.
- Executive Compensation Details:
- Molly Hemmeter (CEO): Granted 42,500 options, 14,167 standard RSUs, and 22,794 performance-based RSUs (LTIP).
- Gregory Skinner (CFO): Granted 18,550 options, 6,183 standard RSUs, and 9,930 performance-based RSUs (LTIP).
- Steven Bitler (VP Corporate Technology): Granted 2,185 options.
- Performance Targets: The specific EPS targets for fiscal year 2021 required to trigger the LTIP payouts are not detailed in this filing and should be verified in the company's proxy statement or annual report.